Sunil Healthcare Limited

BSE:537253 Stock Report

Market Cap: ₹851.1m

Sunil Healthcare Past Earnings Performance

Past criteria checks 0/6

Sunil Healthcare has been growing earnings at an average annual rate of 28.1%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 6.4% per year.

Key information

28.1%

Earnings growth rate

28.1%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate6.4%
Return on equity-2.7%
Net Margin-2.1%
Next Earnings Update13 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sunil Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:537253 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24892-181260
31 Mar 24902-181310
31 Dec 23901-151350
30 Sep 23927-141370
30 Jun 23996191410
31 Mar 231,105671520
31 Dec 221,2121021550
30 Sep 221,2751251560
30 Jun 221,2601041460
31 Mar 221,192641760
31 Dec 211,108181380
30 Sep 211,015-31340
30 Jun 21952-21270
31 Mar 21906-61270
31 Dec 20831-71320
30 Sep 20796-61320
30 Jun 20735-181320
31 Mar 20700-241330
31 Dec 19731-211340
30 Sep 19751-221330
30 Jun 19799-91270
31 Mar 19809-61260
31 Mar 18913451260
31 Mar 171,085501120
31 Dec 16965621020
30 Sep 1693460940
30 Jun 1686253960
31 Mar 1681652940
31 Dec 15762531630
30 Sep 15712481620
30 Jun 15738481610
31 Mar 1572640860
31 Dec 14718371460
30 Sep 14668401420
30 Jun 14635381390
31 Mar 14617331370
31 Dec 13566301230

Quality Earnings: 537253 is currently unprofitable.

Growing Profit Margin: 537253 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 537253 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.1% per year.

Accelerating Growth: Unable to compare 537253's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 537253 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).


Return on Equity

High ROE: 537253 has a negative Return on Equity (-2.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies